Table 2.
Clinical Findings After Low-Dose and High-Dose Radioactive Iodine Therapy According to Tumor Size
| Tumor size: 1–2 cm | Tumor size: ≤1 cm | |||||
|---|---|---|---|---|---|---|
| LO group (n=35) | HI group (n=56) | p-Value | LO group (n=61) | HI group (n=24) | p-Value | |
| TgAb positive | 0 (0%) | 2 (3.6%) | 2 (3.3%) | 0 (0%) | ||
| TgAb negative | 35 (100%) | 54 (96.4%) | 59 (96.7%) | 24 (100%) | ||
| sTg <1 ng/mL | 34 (97.1%) | 51 (91.0%) | 59 (96.7%) | 22 (91.7%) | ||
| sTg ≥1 ng/mL | 1 (2.9%) | 3 (5.4%) | 0 (0%) | 2 (8.3%) | ||
| Neck ultrasonography | ||||||
| Normal | 35 (100%) | 55 (98.2%) | 61 (100%) | 24 (100%) | ||
| Suspicious | 0 (0%) | 1 (1.8%) | 0 (0%) | 0 (0%) | ||
| Cytology: normal | 0 | 1 | ||||
| Diagnostic whole body scan | ||||||
| No uptake | 32 (91.4%) | 54 (96.4%) | 54 (88.5%) | 24 (100%) | ||
| Thyroid bed uptake | 3 (8.6%) | 2 (3.6%) | 7 (11.5%) | 0 (0%) | ||
| Pathological uptake | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
| Successful ablation | 34/35 (97%) | 50/56 (89%) | 0.243 | 59/61 (97%) | 22/24 (92%) | 0.304 |
TgAb, serum antithyroglobulin antibody; sTg, serum-stimulated thyroglobulin.